Gennex Laboratories Ltd. (BSE: 531739) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹223 Cr, it ranks #2,556 by market cap among the 6,197 Indian listed companies on FinBizNet, and #36 of 63 in Pharmaceuticals. At ₹9.35 (as of 16 Nov 2026), the share price is 42.2% below its 52-week high of ₹16.18 and 32.6% above its 52-week low of ₹7.05. The share price is down 33.9% over one year and down 0.9% over three months.
| Current Price | ₹9.35 |
|---|---|
| Market Cap | ₹223 Cr |
| BSE Code | 531739 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 10.6 |
| Return on Equity | 9.82% |
| Return on Assets | 4.11% |
| 52-Week Range | ₹7.05 – ₹16.18 |
| 1-Year Price Change | -33.9% |
| 3-Month Price Change | -0.9% |
| Beta (1Y) | 0.86 |
| Headquarters | Hyderabad, Telangana |
| Website | www.gennexlab.com |
Delivery averaged 77.2% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam. Gennex Laboratories Limited was formerly known as Prudential Pharmaceuticals Limited and changed its name to Gennex Laboratories Limited in September 2007. Gennex Laboratories Limited was incorporated in 1985 and is base
1. Bulk Drugs,Biotech Products and Intermediates-This segment manufactures bulk drugs, intermediates, and biotech products. 2. Other-0 3. Segment Adjustment-0
1. Bulk Drugs, Biotech Products and Intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Gennex Laboratories Ltd. | ₹223 Cr | 10.6 | 9.82% | — | -33.9% |
Listed by market capitalisation. Ratios are shown for context only.
Gennex Laboratories Ltd. is trading at ₹9.35, with a market capitalisation of ₹223 Cr.
Gennex Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Gennex Laboratories Ltd. has a P/E of 10.6 and a return on equity of 9.82%.
Gennex Laboratories Ltd. is listed on the BSE under the scrip code 531739.
Gennex Laboratories Ltd.'s share price is down 33.9% over one year and down 0.9% over three months. Its 52-week range is ₹7.05 to ₹16.18.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.